Stephen J. DiPalma

CIK 1426479 · Interim CFO · last filed 2021-05-18

Stephen J. DiPalma is an Interim CFO who has filed 5 SEC Form 4 insider transactions across 2 companies since 2008. The most recent filing, for INZY, was dated May 18, 2021. 3 SEC filings were submitted jointly with Galena Biopharma, Inc.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Disclosed Exposure

Companies

Total Filings

Lifetime Open-Market Net

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

RXII price and trades

Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.

Shares held

Shares owned after each reported transaction on this company (direct holdings as reported).

Open-market buying and selling

by month

Dollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.

Exposure by company

latest

OfficerDirector10% owner* stale (no filing in 3 yrs)

Most recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.

Filer Profile

Reported Address

C/O SPERO THERAPEUTICS, INC.
675 MASSACHUSETTS AVENUE, 14TH FLOOR
CAMBRIDGE, MA 02139

Related Filers

Galena Biopharma, Inc. — 3 joint filings, latest 2009-01-20

Inozyme Pharma, Inc. — 2 joint filings, latest 2021-05-18

Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.

Symbol	Role	Shares	Price	Disclosed Exposure	Lifetime OM Net	Filings	Latest Filed
Inozyme Pharma, Inc. (INZY) Delisted	Interim CFO	—	$4.00	—	$0	1	2021-05-18
SELLAS Life Sciences Group, Inc. (RXII) Delisted	CFO, EVP, Secretary	—	—	—	$0	2	2009-01-20

Recent Filings

5 filings

Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.

Filed	Symbol	Action	Net Shares	Net $	Link
2021-05-18	Inozyme Pharma, Inc. (INZY) Delisted	Grant (A)	—	$0	EDGAR
2016-08-01	—	Buy (P)	+100,603	$10.0K
2014-12-30	—	Buy (P)	+249,252	$25.0K
2009-01-20	SELLAS Life Sciences Group, Inc. (RXII) Delisted	Grant (A)	—	$0	EDGAR
2008-04-22	SELLAS Life Sciences Group, Inc. (RXII) Delisted	Grant (A)	—	$0	EDGAR

Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.